TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Ytterby Life Science AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
124
|
113 | |
| Financial expenses |
0
|
0 | |
| Earnings before taxes |
31
|
31 | |
| EBITDA |
21
|
22 | |
| Total assets |
55
|
49 | |
| Current assets |
52
|
46 | |
| Current liabilities |
5
|
5 | |
| Equity capital |
45
|
40 | |
| - share capital |
5
|
4 | |
| Employees (average) |
1
|
1
|
1 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
81.8%
|
81.6% | |
| Turnover per employee |
124
|
113 | |
| Profit as a percentage of turnover |
25.0%
|
27.4% | |
| Return on assets (ROA) |
56.4%
|
63.3% | |
| Current ratio |
1040.0%
|
920.0% | |
| Return on equity (ROE) |
68.9%
|
77.5% | |
| Change turnover |
11
|
17 | |
| Change turnover % |
-21%
|
9%
|
17% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
0%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.